Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Neurocrine Biosciences, Inc. (NBIX) vs United Therapeutics Corporation (UTHR)

Neurocrine Biosciences, Inc. and United Therapeutics Corporation are both Drug Manufacturers Specialty & Generic companies. United Therapeutics Corporation is the larger, with a market value of $20.3B against $14.1B — 1.4× the size. United Therapeutics Corporation trades at the lower P/E: 15.7× against 19.6×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 2.49%. United Therapeutics Corporation has the higher net margin (41.6% vs 20.9%) and the higher return on invested capital (23.4% vs 15.0%). Across the 21 metrics below, United Therapeutics Corporation leads on 11 and Neurocrine Biosciences, Inc. on 10.

Valuation

Metric NBIX UTHR Drug Manufacturers Specialty & Generic median
P/E 19.63 15.70 20.14
P/S 4.14 6.42 2.25
P/B 3.78 3.16 1.90
Price to free cash flow 16.06 18.62 16.54
EV/EBITDA 16.65 11.98 12.29
EV/Sales 4.11 5.67 2.56
Earnings yield 5.09% 6.37% (2.99%)
Free cash flow yield 6.23% 5.37% 0.00%

Profitability

Metric NBIX UTHR Drug Manufacturers Specialty & Generic median
Gross margin 97.94% 86.14% 53.94%
Operating margin 23.56% 44.44% 0.00%
Net margin 20.91% 41.56% 0.00%
Free cash flow margin 25.80% 34.65% 0.00%
Return on equity 22.09% 19.32% (0.40%)
Return on assets 15.26% 17.33% (3.32%)
Return on invested capital 15.04% 23.44% 0.00%

Growth

Metric NBIX UTHR Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 34.42% 2.49% 10.01%
EPS growth (last fiscal year) 41.95% 13.07% —
Revenue growth, 5-year CAGR 22.29% 16.50% 6.74%
Net income growth, 5-year CAGR 3.28% 20.99% 0.00%

Health

Metric NBIX UTHR Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.00 0.05
Current ratio 1.87 5.73 2.31
Net debt to EBITDA (2.33) (1.85) 0.85

Dividend

Metric NBIX UTHR Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric NBIX UTHR Drug Manufacturers Specialty & Generic median
Market cap 14.12b 20.25b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack